Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology and Venereology (EADV) Congress
Phase IIb data on remibrutinib (LOU064), an oral Bruton’s tyrosine kinase inhibitor, for people living with chronic spontaneous urticaria to be highlighted at EADV
Results of analysis at Week 52 from Phase IIb trial of ianalumab (VAY736), a dual mode of action B-cell activating factor receptor inhibitor in Sjögren’s syndrome, to be unveiled at International Symposium on Sjögren’s Syndrome
Total of 37 abstracts across both meetings will be presented, reflecting Novartis ambition to improve the lives of those affected by a range of immunological diseases
Basel, September 2, 2022 — Novartis today announced it will showcase data from its leading immunology portfolio and emerging pipeline at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress and the 15th International Symposium on Sjögren’s Syndrome (ISSS), both occurring September 7–10, 2022. A total of 37 abstracts will be shared across both meetings, spanning hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU), Sjögren’s syndrome, axial spondyloarthritis, and psoriasis.

“These data – including late-breaking results from our pivotal trials for Cosentyx® in hidradenitis suppurativa – demonstrate both the strength of our portfolio, and our commitment to pioneering the medicines of tomorrow in immunology,” said Angelika Jahreis M.D., Ph.D., FAAD, Global Head Development Unit Immunology and Clinical Development Excellence, Novartis. “We are focusing our development efforts on immunological diseases with significant unmet need, and hope that we will soon be able to provide more treatment options to patients to manage their conditions.”

The Novartis ambition is to reduce the suffering from immunological conditions, which affect up to 4.5% of the world’s population and can have a significant impact on quality of life1. In addition to its comprehensive portfolio of innovative therapy options, Novartis is exploring potential biologic and oral treatments with various mechanisms of action in HS, developing medicines that could help those living with CSU achieve complete symptom control, and advancing research in Sjögren’s syndrome, for which there are currently no disease-modifying treatments available2,3.

To assess and elevate the patient perspective at every stage of its clinical research, Novartis will also share the latest findings from a number of patient-based initiatives at EADV, including the global Psoriasis and Beyond study exploring the impact of psoriatic disease on mental health. Results from a comprehensive social media monitoring program to help illuminate the significant unmet needs of people living with HS will also be presented.

Highlights at ISSS
see & read more on
https://www.novartis.com/news/media-releases/novartis-highlights-depth-immunology-pipeline-novel-data-key-upcoming-international-congresses

For questions about the site or required registration, please contact media.relations@novartis.com.

References

1. Scientific American. The Terrible Toll of 76 Autoimmune Diseases [online]. Available from: https://www.scientificamerican.com/article/the-terrible-toll-of-76-autoimmune-diseases/ [Last accessed: August 2022].
2. Sjögren's Foundation. Understanding Sjögren's - Symptoms [online]. Available from: https://www.sjogrens.org/understanding-sjogrens/symptoms [Last accessed: August 2022].
3. NHS. Treatment - Sjögren's syndrome [online]. Available from: https://www.nhs.uk/conditions/sjogrens-syndrome/treatment/ [Last accessed: August 2022].